0.1492

1.84% -0.0027

Viracta Therapeutics Inc (VIRX)

Overview News Price History Option Chain Financials Discussions Forecast

Viracta Therapeutics Inc stock is traded at $0.1492, with a volume of 97,661. It is down -1.84% in the last 24 hours and down -37.87% over the past month. Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

Previous Close:

$0.1519

Open:

$0.148

24h Volume:

97,661

Relative Volume:

0.10

Market Cap:

$5.79M

Revenue:

Net Income/Loss:

$-51.06M

P/E Ratio:

-0.1081

EPS:

-1.38

Net Cash Flow:

$-40.03M

1W Performance:

-5.57%

1M Performance:

-37.87%

6M Performance:

-81.36%

1Y Performance:

-72.60%

1-Day Range:

$0.1445

$0.1549

1-Week Range:

$0.1315

$0.1579

52-Week Range:

$0.1315

$1.31

Viracta Therapeutics Inc Stock (VIRX) Company Profile

Name

Viracta Therapeutics Inc

Sector

Healthcare (1195)

Industry

Biotechnology (683)

Phone

858-400-8470

Address

2533 S COAST HWY 101, CARDIFF

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

VIRX's Discussions on Twitter

Compare VIRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VIRX	0.1502	5.79M	0	-51.06M	-40.03M	-1.38
VRTX	449.28	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	746.98	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	592.38	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	249.29	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	103.94	24.49B	3.30B	-501.07M	1.03B	11.54

Viracta Therapeutics Inc Stock (VIRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-01-22	Initiated	RBC Capital Mkts	Outperform
May-03-21	Initiated	H.C. Wainwright	Buy
Apr-26-21	Initiated	SVB Leerink	Outperform
Mar-25-21	Initiated	Evercore ISI	Outperform

Viracta Therapeutics Inc Stock (VIRX) Latest News

Nov 17, 2024

Royal Bank of Canada Cuts Viracta Therapeutics (NASDAQ:VIRX) Price Target to $2.00 - Defense World

Nov 17, 2024

Nov 15, 2024

VIRX stock touches 52-week low at $0.15 amid market challenges - Investing.com UK

Nov 15, 2024

Nov 14, 2024

Viracta Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 13, 2024

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire

Nov 13, 2024

Head and Neck Cancer Market Expected to Reach $9.07 Billion by 2030, Growing at 16.2% CAGR As Revealed In N... - WhaTech

Nov 13, 2024

Natural Killer T-Cell Lymphoma Market 2024 Projections, - openPR

Nov 13, 2024

Nov 08, 2024

Viracta Thera pins hopes on lead lymphoma program - The Pharma Letter

Nov 08, 2024

Nov 07, 2024

VIRX stock touches 52-week low at $0.18 amid market challenges - Investing.com UK

Nov 07, 2024

Nov 06, 2024

Viracta Therapeutics cuts workforce to focus on cancer program - Investing.com

Nov 06, 2024

Viracta Therapeutics cuts workforce to focus on cancer program By Investing.com - Investing.com Canada

Nov 06, 2024

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma - The Manila Times

Nov 06, 2024

Viracta Therapeutics Announces Reprioritization of - GlobeNewswire

Nov 06, 2024

Viracta (VIRX) Cuts 42% of Workforce, Restructures Board Amid Strategic Shift | VIRX Stock News - StockTitan

Nov 06, 2024

Nov 04, 2024

Pharma takes aim at a wily foe — the Epstein-Barr virus - Yahoo Finance

Nov 04, 2024

Oct 28, 2024

T-cell Lymphoma Market Segments Analysis Report 2024-2031 - InsightAce Analytic

Oct 28, 2024

Oct 24, 2024

Advanced Gastric Carcinoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail

Oct 24, 2024

Oct 22, 2024

Peripheral T-Cell Lymphoma Market Expected to Experience Major - openPR

Oct 22, 2024

Oct 16, 2024

Head and Neck Cancer Market Share, Size, Growth and Forecast to 2031 - InsightAce Analytic

Oct 16, 2024

Oct 10, 2024

Natural Killer T-Cell Lymphoma Market Trends and Growth - openPR

Oct 10, 2024

Sep 30, 2024

Viracta Therapeutics' SWOT analysis: narrowed focus shapes stock outlook By Investing.com - Investing.com South Africa

Sep 30, 2024

Viracta Therapeutics' SWOT analysis: narrowed focus shapes stock outlook - Investing.com India

Sep 30, 2024

Sep 19, 2024

Head and Neck Cancer Market to Reach $9.07 Billion by 2030, Growing at 16.2% CAGR - WhaTech

Sep 19, 2024

Sep 11, 2024

Ionis Pharmaceuticals announces $500 million public offering | Biotechnology | The Pharmaletter - The Pharma Letter

Sep 11, 2024

Sep 09, 2024

The Psychology of Viracta Therapeutics Inc Inc. (VIRX) Price Performance: Understanding Market Sentiment - The InvestChronicle

Sep 09, 2024

Sep 04, 2024